Tags

Type your tag names separated by a space and hit enter

Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings.
Front Neurol. 2019; 10:253.FN

Abstract

Multiple sclerosis (MS) is a chronic autoimmune neurological disease that typically affects young adults, causing irreversible physical disability and cognitive impairment. Alemtuzumab, administered intravenously as 2 initial courses of 12 mg/day (5 consecutive days at baseline, and 3 consecutive days 12 months later), resulted in significantly greater improvements in clinical and MRI outcomes vs. subcutaneous interferon beta-1a over 2 years in patients with active relapsing-remitting MS (RRMS) who were either treatment-naive (CARE-MS I; NCT00530348) or had an inadequate response to prior therapy (CARE-MS II; NCT00548405). Efficacy with alemtuzumab was maintained over 7 years in subsequent extension studies (NCT00930553; NCT02255656), in the absence of continuous treatment and with a consistent safety profile. There is an increased incidence of autoimmune events in patients treated with alemtuzumab (mainly thyroid events, but also immune thrombocytopenia and nephropathy), which imparts a need for mandatory safety monitoring for 4 years following the last treatment. The risk management strategy for alemtuzumab-treated patients includes laboratory monitoring and a comprehensive patient education and support program that enables early detection and effective management of autoimmune events, yielding optimal outcomes for MS patients. Here we provide an overview of tools and techniques that have been implemented in real-world clinical settings to reduce the burden of monitoring for both patients and healthcare providers, including customized educational materials, the use of social media, and interactive online databases for managing healthcare data. Many practices are also enhancing patient outreach efforts through coordination with specialized nursing services and ancillary caregivers. The best practice recommendations for safety monitoring described in this article, based on experiences in real-world clinical settings, may enable early detection and management of autoimmune events, and help with implementation of monitoring requirements while maximizing the benefits of alemtuzumab treatment for MS patients.

Authors+Show Affiliations

Vancouver Coastal Health, Vancouver, BC, Canada.University of British Columbia, Vancouver, BC, Canada.University of British Columbia, Vancouver, BC, Canada.Neurology Center of San Antonio, San Antonio, TX, United States.North Central Neurology Associates, Cullman, AL, United States.Azienda Ospedaliero Universitaria San Luigi, Orbassano, Italy.OhioHealth Neurological Physicians, Columbus, OH, United States.Oslo University Hospital Ullevål and Institute of Clinical Medicine, University of Oslo, Oslo, Norway.Clinical Research Center (CIC), INSERM 1434, Strasbourg University, Strasbourg, France.Imperial College Healthcare NHS Trust, London, United Kingdom.University of Zagreb, School of Medicine and University Medical Center, Zagreb, Croatia.Stanford Healthcare, Palo Alto, CA, United States.Klinik für Neurologie und Palliativmedizin, Cologne, Germany.Clinic of Neurology with Institute of Translational Neurology, University Hospital Müenster, Müenster, Germany.El Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Hospital Clínico San Carlos, Madrid, Spain.Neurology Associates, Maitland, FL, United States.Revalidatie & MS Centrum, Overpelt, Belgium.Center of Clinical Neuroscience, University Clinic Carl Gustav Carus, Dresden, Germany.Sanofi, Cambridge, MA, United States.Rehabilitation & MS-Centre Overpelt, Hasselt University, Hasselt, Belgium.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

30967831

Citation

Barclay, Krista, et al. "Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings." Frontiers in Neurology, vol. 10, 2019, p. 253.
Barclay K, Carruthers R, Traboulsee A, et al. Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings. Frontiers in neurology. 2019;10:253.
Barclay, K., Carruthers, R., Traboulsee, A., Bass, A. D., LaGanke, C., Bertolotto, A., Boster, A., Celius, E. G., de Seze, J., Cruz, D. D., Habek, M., Lee, J. M., Limmroth, V., Meuth, S. G., Oreja-Guevara, C., Pagnotta, P., Vos, C., Ziemssen, T., Baker, D. P., & Wijmeersch, B. V. (2019). Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings. Frontiers in Neurology, 10, 253. https://doi.org/10.3389/fneur.2019.00253
Barclay K, et al. Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings. Frontiers in neurology. 2019;10:253. PubMed PMID: 30967831.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings. AU - Barclay,Krista, AU - Carruthers,Robert, AU - Traboulsee,Anthony, AU - Bass,Ann D, AU - LaGanke,Christopher, AU - Bertolotto,Antonio, AU - Boster,Aaron, AU - Celius,Elisabeth G, AU - de Seze,Jérôme, AU - Cruz,Dionisio Dela, AU - Habek,Mario, AU - Lee,Jong-Mi, AU - Limmroth,Volker, AU - Meuth,Sven G, AU - Oreja-Guevara,Celia, AU - Pagnotta,Patricia, AU - Vos,Cindy, AU - Ziemssen,Tjalf, AU - Baker,Darren P, AU - Wijmeersch,Bart Van, Y1 - 2019/03/22/ PY - 2018/09/06/received PY - 2019/02/25/accepted PY - 2019/4/11/entrez PY - 2019/4/11/pubmed PY - 2019/4/11/medline KW - alemtuzumab KW - anti-CD52 monoclonal antibody KW - autoimmune events KW - best practices KW - disease-modifying therapy KW - monitoring KW - real-world settings KW - relapsing-remitting multiple sclerosis SP - 253 EP - 253 JF - Frontiers in neurology VL - 10 N2 - Multiple sclerosis (MS) is a chronic autoimmune neurological disease that typically affects young adults, causing irreversible physical disability and cognitive impairment. Alemtuzumab, administered intravenously as 2 initial courses of 12 mg/day (5 consecutive days at baseline, and 3 consecutive days 12 months later), resulted in significantly greater improvements in clinical and MRI outcomes vs. subcutaneous interferon beta-1a over 2 years in patients with active relapsing-remitting MS (RRMS) who were either treatment-naive (CARE-MS I; NCT00530348) or had an inadequate response to prior therapy (CARE-MS II; NCT00548405). Efficacy with alemtuzumab was maintained over 7 years in subsequent extension studies (NCT00930553; NCT02255656), in the absence of continuous treatment and with a consistent safety profile. There is an increased incidence of autoimmune events in patients treated with alemtuzumab (mainly thyroid events, but also immune thrombocytopenia and nephropathy), which imparts a need for mandatory safety monitoring for 4 years following the last treatment. The risk management strategy for alemtuzumab-treated patients includes laboratory monitoring and a comprehensive patient education and support program that enables early detection and effective management of autoimmune events, yielding optimal outcomes for MS patients. Here we provide an overview of tools and techniques that have been implemented in real-world clinical settings to reduce the burden of monitoring for both patients and healthcare providers, including customized educational materials, the use of social media, and interactive online databases for managing healthcare data. Many practices are also enhancing patient outreach efforts through coordination with specialized nursing services and ancillary caregivers. The best practice recommendations for safety monitoring described in this article, based on experiences in real-world clinical settings, may enable early detection and management of autoimmune events, and help with implementation of monitoring requirements while maximizing the benefits of alemtuzumab treatment for MS patients. SN - 1664-2295 UR - https://www.unboundmedicine.com/medline/citation/30967831/Best_Practices_for_Long_Term_Monitoring_and_Follow_Up_of_Alemtuzumab_Treated_MS_Patients_in_Real_World_Clinical_Settings_ L2 - https://doi.org/10.3389/fneur.2019.00253 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.